Avecho Biotechnology Ltd
Avecho Biotechnology Ltd is a biotechnology company focused on the development of novel therapeutics for the treatment of infectious diseases and immune-mediated conditions.
Business. Avecho Biotechnology Ltd (AVE.AX) is a pharmaceutical company operating within the Healthcare sector, specifically focused on Pharmaceuticals & Medical Research. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange (ASX). As specific operating segment and geographic data are not provided, the company is described at the industry level as a participant in the pharmaceuticals market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Avecho Biotechnology Ltd (AVE.AX) is a pharmaceutical company operating within the Healthcare sector, specifically focused on Pharmaceuticals & Medical Research. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange (ASX). As specific operating segment and geographic data are not provided, the company is described at the industry level as a participant in the pharmaceuticals market.
Avecho Biotechnology Ltd has a fully diluted share count of 3,673,463,679, with no difference between basic and diluted shares outstanding, indicating no immediate dilution risk from stock options or convertible securities. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, suggesting a lack of transparency or availability of recent financial disclosures.
The company's profitability and returns are not available in the current dataset, and no industry_config preferred metrics are provided for comparison. This absence of data limits the ability to assess Avecho's performance relative to its peers in the Pharmaceuticals industry.
Avecho's revenue concentration by segment or geography is not disclosed in the available data, making it difficult to evaluate the company's exposure to specific markets or product lines. Without this information, the risk of over-reliance on a single revenue stream or geographic region cannot be determined.
The company's growth trajectory is unclear, as no numeric deltas or revenue history are provided in the outlook. This lack of data prevents an assessment of Avecho's current and future revenue performance.
The risk assessment indicates a low dilution risk, but the liquidity risk remains unknown due to the absence of balance-sheet inputs and no going-concern language in source documents. This suggests that the company may not have disclosed sufficient financial information to evaluate its short-term solvency or capital structure.
No recent events, such as filings or transcripts, are available in the dataset to provide insight into Avecho's current operations or strategic direction. This lack of recent disclosures may indicate limited public activity or a focus on private development.
- Avecho Biotechnology Ltd has no difference between basic and diluted shares outstanding, indicating no immediate dilution risk.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- No profitability or returns data is available for comparison with industry peers.
- Revenue concentration by segment or geography is not disclosed, limiting the ability to assess market exposure.
- The company's growth trajectory is unclear due to the absence of numeric deltas or revenue history.
- No recent events or disclosures are available to provide insight into Avecho's current operations or strategic direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$1.1M, +42,3% YoY; Operating income +31,4% YoY.
- ▍Revenue A$1.1M, +42,3% YoY
- ▍Operating income +31,4% YoY
- ▍Net income +31,4% YoY
- ▍Free cash flow +32,1% YoY
- ▍Net margin -207.4%
Revenue A$793.6k; Operating income -A$3.4M.
- ▍Revenue A$793.6k
- ▍Operating income -A$3.4M
- ▍Net margin -430.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Avecho Biotechnology Ltd Market data — financials · 2026-05-27